Iloprost Therapy in Patients With Critical Limb Ischemia

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• Patients who fulfill the internationally defined criteria of critical limb ischemia;

• Patients who are not eligible for vascular surgery or angioplasty interventions and

• Patients who are treated with iloprost infusion.

• The treating physician has decided iloprost treatment before study enrollment.

Exclusion Criteria:

• Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.